echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Himalaya announces appointment of chief financial officer

    Himalaya announces appointment of chief financial officer

    • Last Update: 2021-07-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Himalaya Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development and commercialization of new experimental antibody therapies for the treatment of solid tumor cancer based on the Conditional Active Biotechnology (CAB) technology platform in Greater China, today announced the appointment of Nicholas Desjardins ( Deng Ning) is the Chief Financial Officer and Corporate Development Officer
    .


    In this position, he will lead Himalaya's finance and accounting functions, and will be responsible for investor relations and corporate communications


    Carolyn Short, co-founder of Himalaya Therapeutics and president since its establishment in 2014, said: "Dunning brings Himalaya the unique combined experience of China and the United States in finance, operations and biotechnology.
    We believe this will become the Himalaya team.
    An important advantage
    .


    Dunning is the first new executive in a series of new recruits that we plan to expand our development activities in the Greater China region.


    Dunning has 15 years of investment banking experience mainly in the field of biotechnology, including helping multiple companies and raising more than $1.
    4 billion in 17 IPOs in Cowen and Stifel, and in nearly 50 other strategic transactions and capital financings Another 9.
    1 billion USD was raised
    .


    Recently, he led the consulting business of professional merchant bank ASGARD Partners


    "I am very excited to join the company at this important juncture in Himalaya's development trajectory.
    Our main drug candidate enters Phase 2 clinical trials in Greater China, which will help achieve the milestone of continuing to create value for shareholders
    .


    I look forward to working with us.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.